About This Tool

This Ceftaroline Dose Calculator provides dosing recommendations for ceftaroline fosamil, a cephalosporin antibiotic used for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP). It determines the appropriate dose based on patient population (adult or pediatric), indication, and renal function, as defined by creatinine clearance (CrCl).

Understanding the Outputs

The calculator provides a clear, actionable dosing regimen. Key outputs include:

• Recommended Dose: The amount of ceftaroline in milligrams (mg) to be administered.
• Frequency: How often the dose should be given (e.g., every 8 or 12 hours).
• Infusion Time: The standard duration over which the intravenous (IV) dose should be administered, typically 60 minutes.
• Summary Tags: Patient parameters used for the calculation, such as population type, indication, and calculated or entered CrCl, are displayed for quick verification.

How to Use the Calculator

To ensure an accurate dosing recommendation, follow these steps:

• Select Patient Population: Choose between “Adult (≥18y)” and “Pediatric (≥2m)”. This is a critical first step as dosing strategies differ significantly.
• Choose Indication: Select either ABSSSI or CABP, as pediatric dosing varies by indication.
• Specify Renal Function Method:
  • Select “Enter known CrCl” if you have a recent, calculated value.
  • Select “Calculate CrCl” to use the tool’s built-in Cockcroft-Gault calculator for adults. You will need to provide the patient’s age, weight, serum creatinine, and sex.
• Enter Patient Data: Fill in all required fields accurately. Ensure units (e.g., kg/lbs, mg/dL/µmol/L) are correct.
• Calculate and Review: Click the “Calculate Dose” button. The tool will display the recommended regimen along with a note explaining the basis for the dose.

Dosing Overview

Ceftaroline dosing is adjusted based on age, weight (for pediatrics), and renal function. All doses are administered as a 60-minute IV infusion.

Adult Dosing (≥18 years)

Pediatric Dosing (≥2 months to <18 years)

Note: For pediatric patients, the calculated dose should not exceed the standard adult dose of 600 mg.

Switching Therapy

Ceftaroline is available only as an intravenous formulation. Once a patient is clinically stable and meets appropriate criteria, a healthcare provider may consider switching from IV ceftaroline to a suitable oral antibiotic to complete the course of treatment. This decision is based on clinical judgment, local antimicrobial susceptibility patterns, and patient-specific factors.

Missed Dose

In a clinical setting, IV antibiotic administration is managed by healthcare professionals on a fixed schedule. If a dose is missed, staff should follow institutional protocols. It is important to resume the dosing schedule as soon as possible and consult the prescribing provider or a pharmacist for guidance.

Safety Alerts

As with other cephalosporins, ceftaroline use is associated with certain risks. It is contraindicated in patients with known severe hypersensitivity to cephalosporin antibiotics. Other significant warnings and precautions include:

• Hypersensitivity Reactions: Serious and occasionally fatal reactions have been reported. Before initiating therapy, inquire about previous hypersensitivity to penicillins, cephalosporins, or other beta-lactam agents.
• Clostridioides difficile-Associated Diarrhea (CDAD): CDAD has been reported with nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.
• Development of Drug-Resistant Bacteria: Prescribing ceftaroline in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit and increases the risk of developing drug-resistant bacteria.

This is not a complete list of potential adverse effects. Always consult the official prescribing information.

Frequently Asked Questions (FAQ)

• Why is renal function important for ceftaroline dosing in adults? Ceftaroline is primarily eliminated by the kidneys. In patients with impaired renal function (reduced CrCl), the drug is cleared more slowly, requiring a lower dose to avoid accumulation and potential toxicity.
• Does the calculator adjust for renal impairment in pediatric patients? The current prescribing information does not provide specific dose adjustments for pediatric patients with renal impairment. Dosing in this population should be approached with caution and specialist consultation is recommended.
• What is the difference in dosing between ABSSSI and CABP in children? For children aged 2 years and older, a higher dose (15 mg/kg) is recommended for CABP compared to ABSSSI (12 mg/kg) to ensure adequate drug concentrations at the site of infection.
• What happens if the calculated pediatric dose is over 600 mg? The calculator automatically caps the pediatric dose at 600 mg, as this is the maximum recommended single dose for adults. The output will include a note indicating that the dose was capped.
• Can this calculator be used for newborns or infants under 2 months? No. The safety and effectiveness of ceftaroline have not been established in patients younger than 2 months of age. This calculator is only for patients aged 2 months and older.
• Why does the calculator need my sex to calculate CrCl? The calculator uses the Cockcroft-Gault formula, a standard method for estimating creatinine clearance. This formula includes a correction factor for females to account for differences in muscle mass, which influences creatinine production.
• Is there an oral version of ceftaroline? No, ceftaroline fosamil is only available for intravenous administration.
• Can I use this calculator for other infections like sepsis or bacteremia? This calculator is specifically designed for the FDA-approved indications of ABSSSI and CABP. Dosing for other off-label uses may differ and requires clinical judgment and specialist consultation.

References

• Teflaro (ceftaroline fosamil) Prescribing Information. U.S. Food and Drug Administration. Accessed October 2023.
• Zinforo (ceftaroline fosamil) Summary of Product Characteristics. European Medicines Agency. Accessed October 2023.
• Corey GR, Wilcox M, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 Suppl 4:iv41-iv51. doi:10.1093/jac/dkq254
• File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2010;65 Suppl 4:iv73-iv82. doi:10.1093/jac/dkq253